C2I is home to over 25 biotechnology startups with the capability to provide more than 50 life science entrepreneurs a place to call home. Our residents have created over 100 highly skilled jobs and C2I had helped make an economic impact of 450M+ in funds raised in the Commonwealth.
CreaGen Inc. is a premier chemistry-based drug discovery service company that provides cost-effective, high quality discovery research services to biotech and pharmaceutical companies.
Frequency Therapeutics is a platform technology with an initial focus on chronic hearing loss, a potential $10B+ US market with no effective therapeutic solution. Other potential applications include gastrointestinal diseases and diabetes.
SciFluor Life Sciences is a drug discovery company applying expertise in fluorine chemistry to create a portfolio of differentiated best-in-class therapeutics.
Nano-C started operations in 2001, and is a leader in the world of nano-structured carbon materials and chemicals.
SQZ Biotech is a company founded out of the Massachusetts Institute of Technology (MIT). At SQZ, they have developed a high-throughput platform - CellSqueeze - for simple and effective material delivery into cells.
Ankaa Therapeutics is a leader in developing targeted small molecule drugs for personalized therapy.
Snapdragon Chemistry is headquartered in Boston, MA and is a leading provider of flow chemistry solutions and services.
Rilas Technologies provides services in the areas of purification of small molecule drug candidates from early discovery through to clinical phases.
Mercury Therapeutics Inc is a biotechnology company based out of 2 Gill St, Woburn, Massachusetts, United States.
MaxThera's strategy is to limit resistance emergence to combine the use of these new targets in biosynthetic pathways - essential for bacterial survival - with novel structural classes of compounds.
The Augusta founding laboratories have used cutting edge genetic technologies and shRNA screening methodologies to uncover the ROS receptor tyrosine kinase as a cancer survival gene.
Veraquel has developed a transformative technology for the synthesis of peptide drugs, applicable from discovery to large-scale manufacturing by enabling the parallel synthesis of purified peptides.
Aquilus Pharmaceuticals is a privately held biotechnology company specializing in the treatment and management of pain.
At RootPath Genomics, Inc., we have developed a number of proprietary technologies in molecular engineering and computational biology that promise to bring precision medicine to immunotherapy of cancer.
Material Answers LLC specializes in conceptualization and development of innovative polymer material systems for achieving focused performance targets. Material Answers also provides consulting and expert witness services in material science and engineering and chemical engineering.
Rubix Strategies is a technical business think tank firm that delivers innovative solutions [From Research & Development to initial Product Life-Cycle launch] to industries of the technical discipline.
Sequence with Accuracy SeqLL is an industry leading DNA and RNA sequencing service provider, particularly for single molecule sequencing data.
JA Bio Inc. is a startup bio-tech company located at Cambridge in Massachusetts. We are focusing on anti-cancer cell immune therapeutics discovery and development.
The Martin Trust Center for MIT Entrepreneurship provides the expertise, support, and connections MIT students need to become effective entrepreneurs.
Empiriko is a biotechnology company that designs game-changing solutions for drug discovery, development and patient treatment.
LayerBio is developing novel therapies to address unmet needs in ophthalmology, wound care and orthopedics.
The Quantum Technology Group's patent portfolio establishes broad implications for the production of non-toxic quantum dots, while also able to deliver bulk manufacturing.
NanoScience Solutions (NSS) has developed a portfolio of unmatched patented and licensed nanotechnologies that can be used as tangible solutions for immediate and projected needs in the biomedical, defense and intelligence communities.
Founded by leading researchers in the field, DyNuPol, Inc. supplies highly efficient polarizing agents including patent-pending TOTAPOL for use in a variety of areas.
ConsortiaTX, Inc. is a seed stage, pre-clinical bio-therapeutics company that emerged from research laboratories at Brigham & Women’s Hospital and Children’s Hospital in Boston. The company’s intellectual property around food allergies and the human gut microbiome is based on the work of Lynn Bry, M.D., Ph.D., Georg Gerber, M.D., Ph.D. (both at BWH), and Talal Chatilla, Ph.D. (at CHB) and others.